On 9 December 2019,New Jersey-based pharma titan Merck announced it is acquiring biopharmaceutical prospect ArCule,Inc. for 20 dollars a share,or about 2.7 billion dollars.ArCule's lead investigational candidate,ARQ 531,is an oral medication in a phase 2 dose expansion study for the treatment of B-cell malignancies (leukemia).
ARQ 531 is a highly selective, reversible inhibitor that,in early clinical trials, demonstrated a manageable safety profile and early signs of anti-tumour activity for the treatment of patients with relapsed or refactory chronic lymphocytic leukemia (CLL) and Richter's Transformation.*
ArQule CEO Paolo Pucci said:
With this agreement,ArQule's pipeline will benefit from Merck's vast capabilities and determined engagement to benefit the patients who we have always strived to serve.*
ArQule's discovery efforts are focused on the identification and development of novel kinase inhibitors, the company noted.iAll four of its drug candidates are in targeted, biomarker-defined patient populations.*
Merck&Co Inc (MRK), ArQule Inc (ARQC)
Showing posts with label leukemia. Show all posts
Showing posts with label leukemia. Show all posts
Monday, December 9, 2019
Thursday, December 22, 2011
A Slightly High WBC Count:Why You Shouldn't Worry
If someone's white blood cell count is a little high,it often causes considerable fear,according to the anecdotal literature.Your doctor may not seem too worried,however.Why such an aggravating response?What if it's leukemia?
It could be a form of leukemia at a very early stage,of course,but it almost certainly isn't.Leukemia is a rare disorder.About 43,000 Americans were estimated to be diagnosed with it in 2010,for example.Even if it is leukemia,it likely isn't a highly dangerous type or acute phase.If it were,you would be so sick,the symptoms would be more prominent.You would need to be hospitalized.Your blood markers would be quite abnormal,not just a little.
What you probably have is a little cold virus or other infection passing through your system.The doctor has likely seen this many times.That's why,in the absence of other indications,there is little urgency.In that typical family practice,there have probably been few leukemia diagnoses in a given year.That's how rare the dread disease is.So don't worry.Follow your doctor's lead.Get a follow up blood test as recommended.You are almost certainly going to be O.K.
According to the most recent calculation,the five year survival rate for leukemia across the board was about 55% as of 2006.It's definitely a major problem for those relatively few who are ultimately diagnosed with it.They need all the treatment and other support they can get.
About 20% of people with leukemia are walking around undiagnosed,the American Cancer Society estimates.It's because they have few if any symptoms yet or the similarity of their symptoms to those of other diseases.
It could be a form of leukemia at a very early stage,of course,but it almost certainly isn't.Leukemia is a rare disorder.About 43,000 Americans were estimated to be diagnosed with it in 2010,for example.Even if it is leukemia,it likely isn't a highly dangerous type or acute phase.If it were,you would be so sick,the symptoms would be more prominent.You would need to be hospitalized.Your blood markers would be quite abnormal,not just a little.
What you probably have is a little cold virus or other infection passing through your system.The doctor has likely seen this many times.That's why,in the absence of other indications,there is little urgency.In that typical family practice,there have probably been few leukemia diagnoses in a given year.That's how rare the dread disease is.So don't worry.Follow your doctor's lead.Get a follow up blood test as recommended.You are almost certainly going to be O.K.
According to the most recent calculation,the five year survival rate for leukemia across the board was about 55% as of 2006.It's definitely a major problem for those relatively few who are ultimately diagnosed with it.They need all the treatment and other support they can get.
About 20% of people with leukemia are walking around undiagnosed,the American Cancer Society estimates.It's because they have few if any symptoms yet or the similarity of their symptoms to those of other diseases.
Friday, December 2, 2011
Novartis Honored By Fortune Magazine
Swiss health care firm Novartis was honored by Fortune magazine as its Most Admired pharmaceutical company for 2011.It recieved an overall score of 7.02,folowed by Merck at 6.80 and Johnson&Johnson at 6.72.Last year,Novartis came in third.
The rank was decided by a survey of pharmaceutical executives,directors and analysts.They used nine criteria such as investment value and social responsibility.
Novartis is the world's third-largest pharmaceutical firm by sales.
One of its leading products is Gleevec(imatinib),a pill for patients with certain forms of chronic myeloid leukemia(CML) and gastrointestinal stromal tumors(GIST).Gleevec is also approved in the U.S.,EU and Japan for a form of acute lymphoblastic leukemia(ALL) and other blood disorders.It has helped many patients stay in remission for several years.
Novartis also owns the OTC brands Theraflu and Comtrex.The company has an assistance program for uninsured or underinsured patients.
Novartis AG(NVS)
The rank was decided by a survey of pharmaceutical executives,directors and analysts.They used nine criteria such as investment value and social responsibility.
Novartis is the world's third-largest pharmaceutical firm by sales.
One of its leading products is Gleevec(imatinib),a pill for patients with certain forms of chronic myeloid leukemia(CML) and gastrointestinal stromal tumors(GIST).Gleevec is also approved in the U.S.,EU and Japan for a form of acute lymphoblastic leukemia(ALL) and other blood disorders.It has helped many patients stay in remission for several years.
Novartis also owns the OTC brands Theraflu and Comtrex.The company has an assistance program for uninsured or underinsured patients.
Novartis AG(NVS)
Wednesday, November 23, 2011
A Concerning Marker:What High WBC Means
High white blood cell counts can indicate a number of things.They may signal:
infection;
reaction to a drug;
bone marrow disease;
immune system disorder.
Typical causes of high WBC include leukemia;measles;rheumatoid arthritis;stress;and tuberculosis.The number of serious possibilities make further medical attention imperative for the patient with a high WBC.
The normal white blood cell values as expressed in lab results are between 4.0 and 11.0.
infection;
reaction to a drug;
bone marrow disease;
immune system disorder.
Typical causes of high WBC include leukemia;measles;rheumatoid arthritis;stress;and tuberculosis.The number of serious possibilities make further medical attention imperative for the patient with a high WBC.
The normal white blood cell values as expressed in lab results are between 4.0 and 11.0.
Thursday, August 18, 2011
Pfizer Cancer Therapies Move Forward in Europe
The European Medicines Agency has accepted Pfizer's regulatory submissions for review of two investigational compounds.One of them,crizotinib,targets a form of advanced non-small cell lung cancer(NSCLC);the other,bosutinib,is aimed at newly diagnosed chronic myeloid leukemia.Both compounds are believed to inhibit signaling in cancer cells that allows them to grow,survive and reproduce.
Pfizer Oncology says its pipeline is focused on identifying and translating the best scientific breakthroughs into clinical applications across a wide range of cancers.It has biologics and small molecules in clinical development and more than 100 clinical trials underway.
With its wide array of research partners,ranging from individual researchers to academic institutions,Pfizer Oncology strives to deliver the right drug for each patient at the right time to cure or control cancer.
Pfizer is listed on the London and New York stock exchanges under the ticker symbols PFZ and PFE,respectively.CEO Ian Read heads the New York-based company.
Pfizer Oncology says its pipeline is focused on identifying and translating the best scientific breakthroughs into clinical applications across a wide range of cancers.It has biologics and small molecules in clinical development and more than 100 clinical trials underway.
With its wide array of research partners,ranging from individual researchers to academic institutions,Pfizer Oncology strives to deliver the right drug for each patient at the right time to cure or control cancer.
Pfizer is listed on the London and New York stock exchanges under the ticker symbols PFZ and PFE,respectively.CEO Ian Read heads the New York-based company.
Subscribe to:
Posts (Atom)